Back to Archived Journals » Biosimilars » Volume 5

Challenging issues in assessing analytical similarity in biosimilar studies

Authors Chow S

Received 6 March 2015

Accepted for publication 2 April 2015

Published 22 May 2015 Volume 2015:5 Pages 33—39


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Laszlo Endrenyi

Shein-Chung Chow

Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

Abstract: For assessing biosimilarity of biosimilar products, the US Food and Drug Administration (FDA) proposed a stepwise approach for providing totality-of-the-evidence of similarity between a proposed biosimilar product and a US-licensed (reference) product. The stepwise approach starts with an assessment of critical quality attributes (CQAs) that are relevant to clinical outcomes in structural and functional characterization in manufacturing process of the proposed biosimilar product. The FDA suggests that these critical quality–relevant attributes be identified and classified into three tiers depending their criticality or risk ranking. To assist the sponsors, the FDA also suggests some statistical approaches for the assessment of analytical similarity for CQAs from different tiers, namely equivalence test for Tier 1, quality range approach for Tier 2, and descriptive raw data and graphical comparison for Tier 3. In this paper, challenging issues to the FDA's recommended approaches are discussed followed by alternative methods for the assessment of analytical similarity (mainly for CQAs from Tier 1).

Keywords: stepwise approach, critical quality attribute, CQA, equivalence test, quality range approach

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]